Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 0.65% and Operating profit at 24.70% over the last 5 years
2
With a growth in Net Profit of 1934.12%, the company declared Very Positive results in Sep 25
3
With ROE of 5.93%, it has a expensive valuation with a 4.87 Price to Book Value
4
Market Beating performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 2,673 Million (Small Cap)
82.00
NA
0.49%
-0.69
10.80%
3.33
Revenue and Profits:
Net Sales:
178 Million
(Quarterly Results - Sep 2025)
Net Profit:
44 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.11%
0%
0.11%
6 Months
-8.78%
0%
-8.78%
1 Year
64.51%
0%
64.51%
2 Years
109.26%
0%
109.26%
3 Years
65.57%
0%
65.57%
4 Years
59.15%
0%
59.15%
5 Years
101.11%
0%
101.11%
Tibet Aim Pharm., Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.65%
EBIT Growth (5y)
24.70%
EBIT to Interest (avg)
24.78
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.60
Sales to Capital Employed (avg)
0.87
Tax Ratio
21.41%
Dividend Payout Ratio
40.00%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.70%
ROE (avg)
6.15%
Valuation key factors
Factor
Value
P/E Ratio
82
Industry P/E
Price to Book Value
4.87
EV to EBIT
71.13
EV to EBITDA
48.85
EV to Capital Employed
11.08
EV to Sales
5.41
PEG Ratio
NA
Dividend Yield
0.35%
ROCE (Latest)
15.58%
ROE (Latest)
5.93%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
177.50
160.90
10.32%
Operating Profit (PBDIT) excl Other Income
18.70
9.90
88.89%
Interest
0.30
0.10
200.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
44.00
2.70
1,529.63%
Operating Profit Margin (Excl OI)
105.10%
28.50%
7.66%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is 10.32% vs -0.62% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is 1,529.63% vs -72.16% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
643.10
659.00
-2.41%
Operating Profit (PBDIT) excl Other Income
49.50
52.00
-4.81%
Interest
0.50
1.20
-58.33%
Exceptional Items
-0.70
-19.80
96.46%
Consolidate Net Profit
47.50
15.70
202.55%
Operating Profit Margin (Excl OI)
43.20%
39.50%
0.37%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -2.41% vs -21.98% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 202.55% vs -65.94% in Dec 2023
About Tibet Aim Pharm., Inc. 
Tibet Aim Pharm., Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






